Assessment and monitoring of biologic drug adverse events in patients with psoriasis

Tessa Hanley, Marc Handford, Dawn Lavery, Zenas ZN Yiu Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, UKBackground: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events.Objective: The aim of this pap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hanley T, Handford M, Lavery D, Yiu ZZN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Biologics monitoring psoriasis screening safety Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/f31746f798074739988f79dc90dc4482
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f31746f798074739988f79dc90dc4482
record_format	dspace
spelling	oai:doaj.org-article:f31746f798074739988f79dc90dc44822021-12-02T05:48:57ZAssessment and monitoring of biologic drug adverse events in patients with psoriasis2230-326Xhttps://doaj.org/article/f31746f798074739988f79dc90dc44822016-04-01T00:00:00Zhttps://www.dovepress.com/assessment-and-monitoring-of-biologic-drug-adverse-events-in-patients--peer-reviewed-article-PTThttps://doaj.org/toc/2230-326XTessa Hanley, Marc Handford, Dawn Lavery, Zenas ZN Yiu Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, UKBackground: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events.Objective: The aim of this paper was to draw together evidence from the currently available guidelines as a summary of how biologics licensed for the treatment of psoriasis should be monitored for adverse events.Methods: The MEDLINE database was searched to identity the current literature on the safety and screening guidance associated with infliximab, etanercept, adalimumab, ustekinumab, and secukinumab.Limitations: This study was limited by the lack of data evaluating monitoring in patients with psoriasis undergoing treatment with a biologic therapy.Results: This review of the current literature highlights that there are areas of routine screening, which are recommended in current practice, which require further evidence to investigate its true utility.Conclusion: Most screening and monitoring tests performed routinely in clinical practice are supported by minimal clinical evidence, highlighting the need for more studies to evaluate the role and value of the different modalities of screening and monitoring for adverse events in those with psoriasis receiving treatment with biologic therapies. Keywords: biologics, monitoring, psoriasis, screening, safetyHanley THandford MLavery DYiu ZZNDove Medical PressarticleBiologicsmonitoringpsoriasisscreeningsafetyDermatologyRL1-803ENPsoriasis: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 41-54 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biologics monitoring psoriasis screening safety Dermatology RL1-803
spellingShingle	Biologics monitoring psoriasis screening safety Dermatology RL1-803 Hanley T Handford M Lavery D Yiu ZZN Assessment and monitoring of biologic drug adverse events in patients with psoriasis
description	Tessa Hanley, Marc Handford, Dawn Lavery, Zenas ZN Yiu Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester, UKBackground: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events.Objective: The aim of this paper was to draw together evidence from the currently available guidelines as a summary of how biologics licensed for the treatment of psoriasis should be monitored for adverse events.Methods: The MEDLINE database was searched to identity the current literature on the safety and screening guidance associated with infliximab, etanercept, adalimumab, ustekinumab, and secukinumab.Limitations: This study was limited by the lack of data evaluating monitoring in patients with psoriasis undergoing treatment with a biologic therapy.Results: This review of the current literature highlights that there are areas of routine screening, which are recommended in current practice, which require further evidence to investigate its true utility.Conclusion: Most screening and monitoring tests performed routinely in clinical practice are supported by minimal clinical evidence, highlighting the need for more studies to evaluate the role and value of the different modalities of screening and monitoring for adverse events in those with psoriasis receiving treatment with biologic therapies. Keywords: biologics, monitoring, psoriasis, screening, safety
format	article
author	Hanley T Handford M Lavery D Yiu ZZN
author_facet	Hanley T Handford M Lavery D Yiu ZZN
author_sort	Hanley T
title	Assessment and monitoring of biologic drug adverse events in patients with psoriasis
title_short	Assessment and monitoring of biologic drug adverse events in patients with psoriasis
title_full	Assessment and monitoring of biologic drug adverse events in patients with psoriasis
title_fullStr	Assessment and monitoring of biologic drug adverse events in patients with psoriasis
title_full_unstemmed	Assessment and monitoring of biologic drug adverse events in patients with psoriasis
title_sort	assessment and monitoring of biologic drug adverse events in patients with psoriasis
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/f31746f798074739988f79dc90dc4482
work_keys_str_mv	AT hanleyt assessmentandmonitoringofbiologicdrugadverseeventsinpatientswithpsoriasis AT handfordm assessmentandmonitoringofbiologicdrugadverseeventsinpatientswithpsoriasis AT laveryd assessmentandmonitoringofbiologicdrugadverseeventsinpatientswithpsoriasis AT yiuzzn assessmentandmonitoringofbiologicdrugadverseeventsinpatientswithpsoriasis
_version_	1718400269111263232

Assessment and monitoring of biologic drug adverse events in patients with psoriasis

Ejemplares similares